140 related articles for article (PubMed ID: 32387490)
1. Error detection thresholds for routine real time in vivo dosimetry in HDR prostate brachytherapy.
Mason J; Henry A; Bownes P
Radiother Oncol; 2020 Aug; 149():38-43. PubMed ID: 32387490
[TBL] [Abstract][Full Text] [Related]
2. Real-time in vivo dosimetry in high dose rate prostate brachytherapy.
Mason J; Mamo A; Al-Qaisieh B; Henry AM; Bownes P
Radiother Oncol; 2016 Aug; 120(2):333-8. PubMed ID: 27236248
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of an in vivo dosimetry-based source tracking method for afterloading brachytherapy - A phantom study.
Jørgensen EB; Kertzscher G; Buus S; Bentzen L; Hokland SB; Rylander S; Tanderup K; Johansen JG
Med Phys; 2021 May; 48(5):2614-2623. PubMed ID: 33655555
[TBL] [Abstract][Full Text] [Related]
4. Time-resolved clinical dose volume metrics, calculations and predictions based on source tracking measurements and uncertainties to aid treatment verification and error detection for HDR brachytherapy-a proof-of-principle study.
van Wagenberg T; Voncken R; van Beveren C; Berbee M; van Limbergen E; Verhaegen F; Paiva Fonseca G
Phys Med Biol; 2024 Jun; 69(13):. PubMed ID: 38870948
[No Abstract] [Full Text] [Related]
5. Derivation of in vivo source tracking error thresholds for TRUS-based HDR prostate brachytherapy through simulation of source positioning errors.
Poder J; Carrara M; Howie A; Cutajar D; Bucci J; Rosenfeld A
Brachytherapy; 2019; 18(5):711-719. PubMed ID: 31175015
[TBL] [Abstract][Full Text] [Related]
6. HDR prostate brachytherapy plan robustness and its effect on in-vivo source tracking error thresholds: A multi-institutional study.
Poder J; Koprivec D; Dookie Y; Howie A; Cutajar D; Damato AL; Côté N; Petasecca M; Bucci J; Rosenfeld A
Med Phys; 2022 Jun; 49(6):3529-3537. PubMed ID: 35388456
[TBL] [Abstract][Full Text] [Related]
7. Towards real time in-vivo rectal dosimetry during trans-rectal ultrasound based high dose rate prostate brachytherapy using MOSkin dosimeters.
Poder J; Howie A; Brown R; Bucci J; Rosenfeld A; Enari K; Schreiber K; Carrara M; Bece A; Malouf D; Cutajar D
Radiother Oncol; 2020 Oct; 151():273-279. PubMed ID: 32798597
[TBL] [Abstract][Full Text] [Related]
8. Time-resolved in vivo dosimetry for source tracking in brachytherapy.
Johansen JG; Rylander S; Buus S; Bentzen L; Hokland SB; Søndergaard CS; With AKM; Kertzscher G; Tanderup K
Brachytherapy; 2018; 17(1):122-132. PubMed ID: 28943129
[TBL] [Abstract][Full Text] [Related]
9. 3D dose reconstruction based on in vivo dosimetry for determining the dosimetric impact of geometric variations in high-dose-rate prostate brachytherapy.
Jørgensen EB; Buus S; Bentzen L; Hokland SB; Rylander S; Kertzscher G; Beddar S; Tanderup K; Johansen JG
Radiother Oncol; 2022 Jun; 171():62-68. PubMed ID: 35033604
[TBL] [Abstract][Full Text] [Related]
10. 3D source tracking and error detection in HDR using two independent scintillator dosimetry systems.
Linares Rosales HM; Johansen JG; Kertzscher G; Tanderup K; Beaulieu L; Beddar S
Med Phys; 2021 May; 48(5):2095-2107. PubMed ID: 33222208
[TBL] [Abstract][Full Text] [Related]
11. Multi-needle Localization with Attention U-Net in US-guided HDR Prostate Brachytherapy.
Zhang Y; Lei Y; Qiu RLJ; Wang T; Wang H; Jani AB; Curran WJ; Patel P; Liu T; Yang X
Med Phys; 2020 Jul; 47(7):2735-2745. PubMed ID: 32155666
[TBL] [Abstract][Full Text] [Related]
12. Development of patient and catheter specific error thresholds for high dose rate prostate brachytherapy.
Koprivec D; Belanger C; Beaulieu L; Chatigny PY; Rosenfeld A; Cutajar D; Petasecca M; Howie A; Bucci J; Poder J
Med Phys; 2024 Mar; 51(3):2144-2154. PubMed ID: 38308854
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric benefits and preclinical performance of steerable needles in HDR prostate brachytherapy.
de Vries M; Christianen MEMC; Luthart L; de Vries KC; Kolkman-Deurloo IKK; van den Dobbelsteen JJ
Med Eng Phys; 2024 Jun; 128():104177. PubMed ID: 38789214
[TBL] [Abstract][Full Text] [Related]
14. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
15. Identifying afterloading PDR and HDR brachytherapy errors using real-time fiber-coupled Al(2)O(3):C dosimetry and a novel statistical error decision criterion.
Kertzscher G; Andersen CE; Siebert FA; Nielsen SK; Lindegaard JC; Tanderup K
Radiother Oncol; 2011 Sep; 100(3):456-62. PubMed ID: 21963285
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial.
Major T; Polgár C; Jorgo K; Stelczer G; Ágoston P
Brachytherapy; 2017; 16(3):608-615. PubMed ID: 28325472
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous automatic segmentation of multiple needles using 3D ultrasound for high-dose-rate prostate brachytherapy.
Hrinivich WT; Hoover DA; Surry K; Edirisinghe C; Montreuil J; D'Souza D; Fenster A; Wong E
Med Phys; 2017 Apr; 44(4):1234-1245. PubMed ID: 28160517
[TBL] [Abstract][Full Text] [Related]
18. In vivo rectal wall measurements during HDR prostate brachytherapy with MOSkin dosimeters integrated on a trans-rectal US probe: Comparison with planned and reconstructed doses.
Carrara M; Tenconi C; Rossi G; Borroni M; Cerrotta A; Grisotto S; Cusumano D; Pappalardi B; Cutajar D; Petasecca M; Lerch M; Gambarini G; Fallai C; Rosenfeld A; Pignoli E
Radiother Oncol; 2016 Jan; 118(1):148-53. PubMed ID: 26796593
[TBL] [Abstract][Full Text] [Related]
19. Adaptation of the CVT algorithm for catheter optimization in high dose rate brachytherapy.
Poulin E; Fekete CA; Létourneau M; Fenster A; Pouliot J; Beaulieu L
Med Phys; 2013 Nov; 40(11):111724. PubMed ID: 24320432
[TBL] [Abstract][Full Text] [Related]
20. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.
Martinez AA; Pataki I; Edmundson G; Sebastian E; Brabbins D; Gustafson G
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):61-9. PubMed ID: 11163498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
